Fauci to FDA: ‘I Got Your Back’ on COVID-19 Vaccine Safety Standards

September 25, 2020by Eric Stirgus and Nika Chaturvedi, The Atlanta Journal-Constitution (TNS)
Anthony Fauci, director of National Institute of Allergy and Infectious Diseases at NIH, testifies during a Senate Health, Education, and Labor and Pensions Committee on Capitol Hill, in Washington, D.C., on October 23, 2020. (Graeme Jennings/Pool/Abaca Press/TNS)

ATLANTA — The federal government’s top infectious disease official attempted to reassure the public Thursday that he’ll support safety standards set by federal officials for any COVID-19 vaccines and their work won’t be swayed by politics.

“If (U.S. Food and Drug Administration officials) come and say this is the way we should do it, I’ve got your back on that,” Dr. Anthony Fauci said in an online discussion organized by Emory University.

The remarks came in response to a question from Dr. Sanjay Gupta, an associate Emory University professor and CNN medical correspondent who moderated the discussion, if Fauci will resist efforts to release a vaccine that FDA officials believe is too risky. President Donald Trump said Wednesday that the White House could override the FDA if the agency released tougher standards for the authorization of a vaccine. The comments worried many scientists and medical experts.

Fauci, director of the National Institutes of Health National Institute of Allergy and Infectious Disease, or NIAID, has been the federal government’s point person on COVID-19. Fauci has said a vaccine will likely not be ready before the end of the year and that there will not initially be enough doses for everyone.

Polls show deep skepticism about vaccine safety. Fauci said during Thursday’s 30-minute discussion he’s been disturbed by the reluctance many Americans have about being vaccinated, particularly among Black Americans. While Blacks have been affected by COVID-19 at a higher rate than other groups, many distrust federal scientific research, citing the Tuskegee study, which intentionally misled Black male participants about the purpose of the research and the treatment they received.

“That’s the reason why we have to be extra specially careful about the safety,” Fauci said.

Emory University is actively involved in vaccine treatment and research. It has been part of NIAID’s research consortium since 2007 and is participating with the agency in a closely watched study of a potential vaccine developed by Moderna, a Massachusetts-based biotechnology company. The critical Phase 3 of Moderna’s vaccine trial began in late July.

Dr. Carlos del Rio, executive associate dean of Emory University’s medical school, emphasized the importance of safety throughout each phase of clinical trials.

“In fact, you’re looking at safety more than efficacy,” del Rio said. “As an investigator, it’s our job to ensure the safety and the proper conduct of the study.”

Del Rio said research to determine vaccines are safe would continue after they’re approved by the federal government.

“Looking at safety never really ends,” he said.

The discussion also focused on ongoing COVID-19 mitigation efforts, such as testing.

Dr. Colleen Kraft, an associate professor in the Department of Medicine Division of Infectious Diseases at Emory University’s medical school, said the prospect of daily testing at home might happen if the pandemic continues for a long time.

“I think there’s going to be a middle ground where we can have rapid diagnostic testing so we can rule people out quickly to be able to do activities, return to school, return to work, and then we also need it obviously for health care settings,” Kraft said.

Gupta also asked Kraft about the possibility of convalescent plasma as a bridge to the vaccine. Convalescent plasma therapy uses blood from people who’ve recovered from an illness to help others recover. Hospitals have been transfusing it directly to sick COVID-19 patients. The treatment is limited not only by supply shortages but also because each person’s plasma has varying levels of antibodies and the transfusions require matching blood types.

Kraft previously worked with convalescent plasma during the Ebola outbreak, but thinks further study is necessary before developing trials around it.

“However, I think one of the things we’re seeing is that it’s a heterogeneous-type of a therapy. So while it is very low-resource and could be widely available, we’ve not really studied and characterized it to the degree to I think, really, is necessary to be able to determine whether or not we’re getting efficacy from it,” Kraft said.

———

©2020 The Atlanta Journal-Constitution (Atlanta, Ga.)

Distributed by Tribune Content Agency, LLC.

Health

In Election's Homestretch, Coronavirus Surge Underscores the Parties' Contrasts
2020 Elections
In Election's Homestretch, Coronavirus Surge Underscores the Parties' Contrasts

WASHINGTON -- In the homestretch of the presidential campaign, with the U.S. coronavirus caseload trending ominously upward, the rival campaigns of President Donald Trump and Joe Biden more than ever are providing a clash of contrasts on how to contain COVID-19 and tend to the virus-battered economy. That was evident in their own... Read More

COVID-19 'Long-haulers' Worry About Coverage, Costs
Health
COVID-19 'Long-haulers' Worry About Coverage, Costs

Andrea Ceresa has been through three gastroenterologists already and now is moving on to her fourth. She's seen an infectious disease specialist, a hematologist, a cardiologist, an ear, nose and throat specialist, a physiatrist and an integrative doctor. She has an appointment coming up with a neuropsychologist... Read More

Repeal Obamacare? Once GOP Dogma, It's Now the Party's Albatross
Health
Repeal Obamacare? Once GOP Dogma, It's Now the Party's Albatross

WASHINGTON - Contempt for the Affordable Care Act Obamacare was so central to Sen. Joni Ernst's 2014 election campaign that the Iowa Republican, in a TV ad promising she'd "unload" on the law, pulled out a handgun and fired repeatedly. "Give me a shot," she asked voters. Six years later, the... Read More

What Happens With COVID-19 'Is in the Hands of the American Public,' CDC Director Says
Health
What Happens With COVID-19 'Is in the Hands of the American Public,' CDC Director Says

COLUMBIA, S.C. -- As families ready to gather next month for Thanksgiving, the director of the Centers for Disease Control and Prevention expressed worry in South Carolina on Thursday about home gatherings further exacerbating the country's COVID-19 caseloads, stressing that people should still social distance, wash hands and wear masks. And... Read More

Don’t Know Any COVID-19 Patients Who’ve Died or Been in the Hospital? That May Explain a Lot
Research
Don’t Know Any COVID-19 Patients Who’ve Died or Been in the Hospital? That May Explain a Lot

Seven months into the pandemic, it’s no secret that plenty of people still downplay the risks of COVID-19, scoffing at mask-wearing and social distancing. Politics clearly feeds that mindset, as suggested by a new Pew Research Center survey in which Republicans were more likely to say... Read More

Pelosi Stays Firm on Coronavirus Relief as a Few Democrats Urge Compromise
Congress
Pelosi Stays Firm on Coronavirus Relief as a Few Democrats Urge Compromise

WASHINGTON — Speaker Nancy Pelosi is trying to keep her caucus together as she holds out for a better coronavirus relief package than the Trump administration’s latest $1.8 trillion proposal, but some Democrats are growing impatient as the window to enact a law before the Nov.... Read More

News From The Well
scroll top